CRBU files 8‑K furnishing Q3 2025 results and business update

Rhea-AI Filing Summary

Caribou Biosciences (CRBU) furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025, and a business update. The press release is included as Exhibit 99.1 and is incorporated by reference.

The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed “filed” under the Exchange Act.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

FALSE000161985600016198562025-11-122025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________

FORM 8-K

________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

________________________________________

Caribou Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

________________________________________

Delaware			001-40631			45-3728228
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
2929 7th Street, Suite 105 Berkeley, California						94710
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 982-6030

N/A

(Former Name or Former Address, if Changed Since Last Report)

________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

CRBU

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, Caribou Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025, and providing a business update. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in any such filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release Issued by Caribou Biosciences, Inc. on November 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									Caribou Biosciences, Inc.
Date:			November 12, 2025			By:			/s/ Rachel E. Haurwitz
									Rachel E. Haurwitz, Ph.D. President and Chief Executive Officer

FAQ

What did Caribou Biosciences (CRBU) announce in this 8‑K?

The company issued a press release with financial results for the quarter ended September 30, 2025, and provided a business update.

Which exhibit contains the press release for CRBU?

The press release is included as Exhibit 99.1.

Is the information in Item 2.02 considered filed or furnished?

It is being furnished and not deemed “filed” under the Exchange Act.

When was the press release issued?

The press release was issued on November 12, 2025.

What period do the reported results cover for CRBU?

The results cover the quarter ended September 30, 2025.

What is Caribou Biosciences’ trading symbol and exchange?

The trading symbol is CRBU on the NASDAQ Global Select Market.